Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) stock went on a downward path that fall over -2.08% on Wednesday, amounting to a one-week price decrease of more than -2.30%. Over the last 12 months, VNDA stock dropped by -28.35%. The one-year VNDA stock forecast points to a potential downside of -1.14, with the average price target set at $28.20 per share. The average equity rating for VNDA stock is currently 2.40, trading closer to a bullish pattern in the stock market.
The market cap for VNDA stock reached $714.63 million, with 54.18 million shares outstanding and 51.84 million shares in the current float. Compared to the average trading volume of 548.01K shares, VNDA reached a trading volume of 523399 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Vanda Pharmaceuticals Inc. (VNDA):
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for VNDA shares is $28.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on VNDA stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Vanda Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 07, 2019. The new note on the price target was released on August 01, 2019, representing the official price target for Vanda Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $26 to $17, while Stifel kept a Hold rating on VNDA stock.
The Average True Range (ATR) for Vanda Pharmaceuticals Inc. is set at 0.53, with the Price to Sales ratio for VNDA stock in the period of the last 12 months amounting to 3.26. The Price to Book ratio for the last quarter was 1.75, with the Price to Cash per share for the same quarter was set at 4.39. Price to Free Cash Flow for VNDA in the course of the last twelve months was 14.18 with Quick ratio for the last quarter at 4.70.
Trading performance analysis for VNDA stock
Vanda Pharmaceuticals Inc. (VNDA) fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.30. With this latest performance, VNDA shares dropped by -12.88% in over the last four-week period, additionally sinking by -12.36% over the last 6 months – not to mention a drop of -28.35% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VNDA stock in for the last two-week period is set at 32.32, with the RSI for the last a single of trading hit 34.49, and the three-weeks RSI is set at 35.03 for Vanda Pharmaceuticals Inc. (VNDA). The present Moving Average for the last 50 days of trading for this stock 15.55, while it was recorded at 13.36 for the last single week of trading, and 14.66 for the last 200 days.
Vanda Pharmaceuticals Inc. (VNDA): A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Vanda Pharmaceuticals Inc. (VNDA) shares currently have an operating margin of +11.26 and a Gross Margin at +88.59. Vanda Pharmaceuticals Inc.’s Net Margin is presently recorded at +13.05.
Return on Total Capital for VNDA is now 10.69, given the latest momentum, and Return on Invested Capital for the company is 12.39. Return on Equity for this stock inclined to 12.39, with Return on Assets sitting at 9.38.
Reflecting on the efficiency of the workforce at the company, Vanda Pharmaceuticals Inc. (VNDA) managed to generate an average of $93,363 per employee. Receivables Turnover for the company is 8.33 with a Total Asset Turnover recorded at a value of 0.72. Vanda Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.70 and a Current Ratio set at 4.70.
Vanda Pharmaceuticals Inc. (VNDA): An earnings per share (EPS) analysis
With the latest financial reports released by the company, Vanda Pharmaceuticals Inc. posted 0.19/share EPS, while the average EPS was predicted by analysts to be reported at 0.01/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 1,800.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VNDA.
An analysis of insider ownership at Vanda Pharmaceuticals Inc. (VNDA)
There are presently around $740 million, in the hands of institutional investors. The top three institutional holders of VNDA stocks are: BLACKROCK INC. with ownership of 9,079,647, which is approximately 1.023% of the company’s market cap and around 3.60% of the total institutional ownership; PALO ALTO INVESTORS LP, holding 4,581,176 shares of the stock with an approximate value of $61.71 million in VNDA stocks shares; and VANGUARD GROUP INC, currently with $58.04 million in VNDA stock with ownership of nearly 19.343% of the company’s market capitalization.
Positions in Vanda Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 100 institutional holders increased their position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by around 7,547,266 shares. Additionally, 73 investors decreased positions by around 9,053,981 shares, while 18 investors held positions by with 38,333,316 shares. The mentioned changes placed institutional holdings at 54,934,563 shares, according to the latest SEC report filing. VNDA stock had 25 new institutional investments in for a total of 1,966,235 shares, while 19 institutional investors sold positions of 5,408,334 shares during the same period.